Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs NetApp Inc. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while NetApp Inc. trades at $237.19 (market cap $45.38B). The key difference: NetApp Inc. is far larger — about 3.6× Halozyme Therapeutics Inc. Common Stock's market cap, and NetApp Inc. pays a 0.9% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and NetApp Inc. for 56 Days on average.
| HALO | NTAP | |
|---|---|---|
Market Cap | $12.58B | $45.38B |
Volume | 2,179,278 | 2,264,311 |
Sector | Health | Technology |
52-Week High | $115.22 | $235.84 |
52-Week Low | $61.63 | $94.11 |
Typical Hold Time | 1 Days | 56 Days |
Enterprise Value | $14.49B | $44.34B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NTAP trades at $235.68, near its 52-week high, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust profitability with a net income margin of 19.19% and ROE of 114.82% for 2025. Recent news highlights strategic AI partnerships with Oracle and Supermicro, enhancing its data infrastructure offerings and market positioning.
The stock presents growth potential driven by AI-driven demand and expanding partnerships, but faces risks from high valuation multiples and competitive pressures. Analyst consensus is mixed with a hold rating bias, though price targets suggest moderate downside from current levels. Investors should weigh strong fundamentals against valuation concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
